Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Accelerating elasticity of demand in sequencing (NovaSeq X adoption) and successful margin expansion drive earnings growth above expectations, defending the premium multiple.
Severe Moat Fade & Pricing War: Emerging competitors force steep price cuts, compressing operating margins below 15% and permanently stalling revenue growth.
Illumina remains the dominant player in genomic sequencing but is transitioning into a mature compounder phase. Having resolved recent antitrust distractions and returned to profitability in 2025, the company faces normalized mid-single-digit growth, requiring disciplined capital allocation and margin protection against emerging competitors.
Illumina remains the dominant player in genomic sequencing but is transitioning into a mature compounder phase. Having resolved recent antitrust distractions and returned to profitability in 2025, the company faces normalized mid-single-digit growth, requiring disciplined capital allocation and margin protection against emerging competitors.
Dominant installed base in short-read sequencing.
High switching costs for integrated clinical diagnostics workflows.
Accelerating elasticity of demand in sequencing and successful expansion into high-margin clinical diagnostics.
Sell. The market prices Illumina for structural hyper-growth, while fundamentals indicate a mature compounder trajectory facing intense pricing pressure.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Intense competition from emerging short-read and long-read sequencing players erodes market share, forcing permanent price reductions that chronically compress operating margins and revenue growth below the 4% floor.
Dominant installed base in short-read sequencing.
High switching costs for integrated clinical diagnostics workflows.
Extensive proprietary reagent and consumable ecosystem.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $1.0B after capex $195.4M, with terminal value at 56.5% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If operating margins clear 18.8%, terminal multiple holds near 20x. If margins break below 15%, multiple compresses toward peer median (18.3x) driving stock toward $75.
If operating margins clear 18.8%, terminal multiple holds near 20x. If margins break below 15%, multiple compresses toward peer median (18.3x) driving stock toward $75.
If operating margins clear 18.8%, holds near 20x. If margins break below 15%, multiple compresses toward peer median (18.3x) driving stock toward $75.
Transitioning from high-growth capacity buildout to a mature phase prioritizing disciplined capital allocation and share repurchases.
Accelerating elasticity of demand in sequencing and successful expansion into high-margin clinical diagnostics.
Maturing academic research budgets and deep-pocketed competitors driving commoditization of the fundamental sequencing layer.
Transitioning from high-growth capacity buildout to a mature phase prioritizing disciplined capital allocation and share repurchases.
Cover shorts or exit remaining long positions if demand elasticity drastically surprises to the upside, pushing sustained revenue growth above 10%.
Upside case depends on the report valuation range and named growth catalysts.
The gap between the market's implied 10.77% growth and grounded 4-5% internal estimates is too wide to ignore. The PEG ratio of 4.93 versus peers at 1.58 indicates extreme relative overvaluation.
Sell. Transition to a mature compounder warrants a severe multiple contraction. Our $98.39 fair value dictates avoiding the stock until the market prices in normalized growth realities.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Intense competition from emerging players erodes market share and forces permanent price reductions, permanently compressing margins and dragging valuation toward the peer median.
Emerging competitors force steep price cuts, compressing operating margins below 15% and permanently stalling revenue growth.
Lower sequencing costs fail to spur sufficient demand volume to mathematically offset the price per gigabase reduction.
Management pursues destructive M&A or fails to manage restructuring maintenance capex, crushing free cash flow conversion.
The five developments that would weaken our investment case.
Failure to maintain operational efficiency amidst industry pricing pressure indicates structural cost inflation or severe discounting. Breaking this profitability floor undermines operating leverage assumptions, leading to multiple compression toward peer averages and lower long-term earnings power.
Current:18.8% for the period ended 2025-12-31
Alert if< 15.0% over any fiscal year
Price per gigabase deflation across high-throughput sequencing compresses gross profitability if volume elasticity fails to compensate. Declining gross margins directly impair reinvestment capacity for next-generation sequencing development and permanently diminish corporate cash flow conversion.
Current:66.1% for the period ended 2025-12-31
Alert if< 62.0% over any fiscal year
Stagnant top-line growth indicates market saturation, prolonged customer budget constraints, or market share losses to emerging sequencing rivals. Sustained underperformance discredits the long-term volume elasticity thesis and triggers structural multiple derating across the franchise.
Current:-0.7% for the period ended 2025-12-31
Alert if< 4.0% year-over-year over any fiscal year
If lower sequencing costs fail to stimulate sufficient consumable run volumes, the business suffers net revenue contraction per installed instrument. Insufficient demand elasticity undermines the economic rationale of platform transitions, compressing recurring high-margin reagent cash flows.
Current:Total revenue was $4.34B for the period ended 2025-12-31 amid NovaSeq X transition
Alert ifAnnual consumable revenue growth < 0.0% year-over-year over any fiscal year
Aggressive defensive expenditures and heightened competitive pressures that diminish cash conversion weaken balance sheet flexibility. Sub-par cash generation restricts capacity for strategic internal development, leaves little margin for operational missteps, and depresses valuation multiples.
Current:Operating cash flow to net income was 1.269 as of the 2026-05-13 analysis date
Alert if
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Accelerating elasticity of demand in sequencing (NovaSeq X adoption) and successful margin expansion drive earnings growth above expectations, defending the premium multiple.
Illumina stabilizes as a mature compounder. Normalized mid-single-digit growth and disciplined capital allocation stabilize the core, but fail to justify the current market premium.
If operating margins clear 18.8%, terminal multiple holds near 20x. If margins break below 15%, multiple compresses toward peer median (18.3x) driving stock toward $75.
Warning level: < 15.0% over any fiscal year. Failure to maintain operational efficiency amidst industry pricing pressure indicates structural cost inflation or severe discounting. Breaking this profitability floor undermines operating leverage assumptions, leading to multiple compression toward peer averages and lower long-term earnings power.
Warning level: < 62.0% over any fiscal year. Price per gigabase deflation across high-throughput sequencing compresses gross profitability if volume elasticity fails to compensate. Declining gross margins directly impair reinvestment capacity for next-generation sequencing development and permanently diminish corporate cash flow conversion.
Warning level: < 4.0% year-over-year over any fiscal year. Stagnant top-line growth indicates market saturation, prolonged customer budget constraints, or market share losses to emerging sequencing rivals. Sustained underperformance discredits the long-term volume elasticity thesis and triggers structural multiple derating across the franchise.
Warning level: Annual consumable revenue growth < 0.0% year-over-year over any fiscal year. If lower sequencing costs fail to stimulate sufficient consumable run volumes, the business suffers net revenue contraction per installed instrument. Insufficient demand elasticity undermines the economic rationale of platform transitions, compressing recurring high-margin reagent cash flows.
Warning level: < 1.0 operating cash flow to net income ratio over any trailing twelve-month period. Aggressive defensive expenditures and heightened competitive pressures that diminish cash conversion weaken balance sheet flexibility. Sub-par cash generation restricts capacity for strategic internal development, leaves little margin for operational missteps, and depresses valuation multiples.
| — |
| $4.58B |
| $4.50B |
| $4.37B |
| $4.34B |
| -1.8% |
| Gross profit | — | $2.97B | $2.74B | $2.86B | $2.87B | -1.2% |
| Operating income | — | $-4.31B | $-1.04B | $-1.08B | $1.19B | — |
| Net income | — | $-4.40B | $-1.16B | $-1.22B | $850.0M | — |
| EPS (diluted) | $5.04 | $-28.00 | $-7.34 | $-7.69 | $5.45 | +2.0% |
| EBITDA | — | $-3.92B | $-608.0M | $-725.0M | $1.46B | — |
| R&D | — | $1.32B | $1.35B | $1.17B | $967.0M | -9.9% |
| SG&A | — | $1.30B | $1.61B | $1.09B | $1.09B | -5.7% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 4,343,000,000 |
|---|---|
| Cost of revenue | 1,473,000,000 |
| Gross profit | 2,870,000,000 |
| Operating expenses | 2,053,000,000 |
| Operating income | 817,000,000 |
| Non-operating items and tax | 33,000,000 |
| Net income | 850,000,000 |
| Total assets | 6,644,000,000 |
|---|---|
| Cash | 1,418,000,000 |
| Current assets | 3,289,000,000 |
| Total liabilities | 3,921,000,000 |
| Current liabilities | 1,585,000,000 |
| Shareholders’ equity | 2,723,000,000 |
Point-in-time financial data used in the 2026-05-13 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 4.6B | -3.9B | -4.4B | 392M | 106M | 286M | 394M | 366M | 0 | — | 991M | — | — | — | — | 2B | 3.6B | 7.7% | — | — | — |
| 2023-12-31 | 4.5B | -608M | -1.2B | 478M | 283M | 195M | 432M | 380M | 0 | — | -1.2B | — | — | — | — | 1B | 2.3B | -4.9% | — | 9.2% | — |
| 2024-12-31 | 4.4B | -725M | -1.2B | 837M | 709M | 128M | 354M | 370M | 116M | — | 491M | — | — | — | — | 1.1B | 2.6B | 13.7% | — | 9.5% | — |
| 2025-12-31 | 4.3B | 1.5B | 850M | 1.1B | 931M | 148M | 270M | 275M | 742M | — | -5M | — | — | — | — | 1.4B | 2.6B | 18.8% | — | 9.1% | — |
ILMN trades at 24.6x forward earnings against a peer median of 18.3x; EV/EBITDA of 20.3x against a peer median of 18.7x; 6 peers.
| Avoid at current prices ($145.70). Re-evaluate entry only if the stock falls into the low-$80s, providing a margin of safety against the $98.39 base case. |
| Danaher Corporation |
| 18.3x |
| 4.7x |
| 16.6x |
| 7.1% |
| 22.9% |
| IDXX | IDEXX Laboratories Inc. | 32.4x | 9.5x | 27.8x | 72.9% | 31.8% |
| WAT | Waters Corporation | 21.5x | 9.2x | 27.1x | 5.2% | 11.7% |
| A | Agilent Technologies Inc. | 17.2x | 4.5x | 16.9x | 19.9% | 22.9% |
